Cargando…
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
BACKGROUND: Smoking and betel nut chewing are well-known risk factors for head and neck squamous cell carcinoma (HNSCC). Smoking is also a strong prognosticator for patients with locally advanced HNSCC receiving induction chemotherapy. Smoking with or without betel nut chewing is a common practice i...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802661/ https://www.ncbi.nlm.nih.gov/pubmed/27001663 http://dx.doi.org/10.1186/s12957-016-0844-2 |
_version_ | 1782422767153446912 |
---|---|
author | Su, Yan-Ye Chien, Chih-Yen Luo, Sheng-Dean Huang, Tai-Lin Lin, Wei-Che Fang, Fu-Min Chiu, Tai-Jan Chen, Yen-Hao Lai, Chi-Chih Hsu, Cheng-Ming Li, Shau-Hsuan |
author_facet | Su, Yan-Ye Chien, Chih-Yen Luo, Sheng-Dean Huang, Tai-Lin Lin, Wei-Che Fang, Fu-Min Chiu, Tai-Jan Chen, Yen-Hao Lai, Chi-Chih Hsu, Cheng-Ming Li, Shau-Hsuan |
author_sort | Su, Yan-Ye |
collection | PubMed |
description | BACKGROUND: Smoking and betel nut chewing are well-known risk factors for head and neck squamous cell carcinoma (HNSCC). Smoking is also a strong prognosticator for patients with locally advanced HNSCC receiving induction chemotherapy. Smoking with or without betel nut chewing is a common practice in Asia. However, little is known regarding whether betel nut chewing can serve as a prognostic factor for smoking patients with locally advanced HNSCC receiving induction chemotherapy. The aim of this study was to evaluate the prognostic impact of betel nut chewing in such patients receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF). METHODS: From January 2010 to December 2012, we retrospectively analyzed 162 smoking patients with locally advanced HNSCC who received induction chemotherapy with TPF at our institution. Background characteristics, including a history of betel nut chewing, were analyzed as potential prognostic factors. RESULTS: Among the 162 smoking patients, 131 patients (81 %) were betel nut chewers, while 31 (19 %) were non-betel nut chewers. One hundred fifty-six (96 %) were men, and 6 (4 %) were women. The median age was 53 years. The overall response rates to induction chemotherapy were 57 and 77 % in patients with and without betel nut chewing history, respectively (P = 0.038). The 2-year progression survival rates were 37 and 67 % in patients with and without betel nut chewing history, respectively (P = 0.004). The 2-year overall survival rates were 47 and 71 % in patients with and without betel nut chewing history, respectively (P = 0.017). Betel nut chewing history was independently associated with a poor response to induction chemotherapy, an inferior progression-free survival rate, and a poor overall survival rate. CONCLUSIONS: Our results indicate that betel nut chewing history is independently associated with poor prognosis in smoking patients with locally advanced HNSCC receiving induction chemotherapy with TPF. Further investigation is warranted to explain this effect of betel nut chewing history on these patients’ prognosis. |
format | Online Article Text |
id | pubmed-4802661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48026612016-03-22 Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil Su, Yan-Ye Chien, Chih-Yen Luo, Sheng-Dean Huang, Tai-Lin Lin, Wei-Che Fang, Fu-Min Chiu, Tai-Jan Chen, Yen-Hao Lai, Chi-Chih Hsu, Cheng-Ming Li, Shau-Hsuan World J Surg Oncol Research BACKGROUND: Smoking and betel nut chewing are well-known risk factors for head and neck squamous cell carcinoma (HNSCC). Smoking is also a strong prognosticator for patients with locally advanced HNSCC receiving induction chemotherapy. Smoking with or without betel nut chewing is a common practice in Asia. However, little is known regarding whether betel nut chewing can serve as a prognostic factor for smoking patients with locally advanced HNSCC receiving induction chemotherapy. The aim of this study was to evaluate the prognostic impact of betel nut chewing in such patients receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF). METHODS: From January 2010 to December 2012, we retrospectively analyzed 162 smoking patients with locally advanced HNSCC who received induction chemotherapy with TPF at our institution. Background characteristics, including a history of betel nut chewing, were analyzed as potential prognostic factors. RESULTS: Among the 162 smoking patients, 131 patients (81 %) were betel nut chewers, while 31 (19 %) were non-betel nut chewers. One hundred fifty-six (96 %) were men, and 6 (4 %) were women. The median age was 53 years. The overall response rates to induction chemotherapy were 57 and 77 % in patients with and without betel nut chewing history, respectively (P = 0.038). The 2-year progression survival rates were 37 and 67 % in patients with and without betel nut chewing history, respectively (P = 0.004). The 2-year overall survival rates were 47 and 71 % in patients with and without betel nut chewing history, respectively (P = 0.017). Betel nut chewing history was independently associated with a poor response to induction chemotherapy, an inferior progression-free survival rate, and a poor overall survival rate. CONCLUSIONS: Our results indicate that betel nut chewing history is independently associated with poor prognosis in smoking patients with locally advanced HNSCC receiving induction chemotherapy with TPF. Further investigation is warranted to explain this effect of betel nut chewing history on these patients’ prognosis. BioMed Central 2016-03-22 /pmc/articles/PMC4802661/ /pubmed/27001663 http://dx.doi.org/10.1186/s12957-016-0844-2 Text en © Su et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Su, Yan-Ye Chien, Chih-Yen Luo, Sheng-Dean Huang, Tai-Lin Lin, Wei-Che Fang, Fu-Min Chiu, Tai-Jan Chen, Yen-Hao Lai, Chi-Chih Hsu, Cheng-Ming Li, Shau-Hsuan Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil |
title | Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil |
title_full | Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil |
title_fullStr | Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil |
title_full_unstemmed | Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil |
title_short | Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil |
title_sort | betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage iv head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802661/ https://www.ncbi.nlm.nih.gov/pubmed/27001663 http://dx.doi.org/10.1186/s12957-016-0844-2 |
work_keys_str_mv | AT suyanye betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil AT chienchihyen betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil AT luoshengdean betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil AT huangtailin betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil AT linweiche betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil AT fangfumin betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil AT chiutaijan betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil AT chenyenhao betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil AT laichichih betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil AT hsuchengming betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil AT lishauhsuan betelnutchewinghistoryisanindependentprognosticatorforsmokingpatientswithlocallyadvancedstageivheadandnecksquamouscellcarcinomareceivinginductionchemotherapywithdocetaxelcisplatinandfluorouracil |